Genitourinary Cancer News

The Society for Immunotherapy of Cancer announced the results of its 2020 election, conducted this spring.

Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy.

Health care providers should begin offering routine HPV vaccination to children as young as age 9 years in order to increase rates of on-time administration, according to an updated American Cancer Society guideline.

The FDA approved avelumab for the first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma, according to a press release from the manufacturer.

For decades, the 5-year survival rate for patients with advanced bladder cancer has remained at about 35%.

Increased rates of certain infections, such as influenza, gastroenteritis, hepatitis and pneumonia, appeared associated with an eventual cancer diagnosis, according to research published in Cancer Immunology Research.

Young adults with early-onset cancers appeared at increased risk for harboring specific germline mutations, according to study results presented at the American Association for Cancer Research Virtual Annual Meeting II.

A combination of nivolumab and ipilimumab conferred durable partial responses among certain patients with treatment-refractory advanced renal cell carcinoma, according to phase 2 study results presented at the virtual ASCO Annual Meeting.

Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Avelumab switch maintenance prolonged OS among patients with advanced urothelial carcinoma whose disease did not progress after first-line chemotherapy, according to study results presented during the ASCO20 Virtual Scientific Program.